SCHEMBL6014452

SCHEMBL6014452

CC(N)CC(C)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.60
TRPA1 O75762 4/20 0.59
AOC3 Q16853 2/20 0.54
SLC6A2 P23975 2/20 0.48
MAOA P21397 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
CYP2A6 P11509 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
RIPK1 Q13546 1/20 0.47
ADRA2A P08913 1/20 0.46
ADRA2C P18825 1/20 0.46
LMNA P02545 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27360069 1.00 TAAR1 (0.60) TAAR1TRPA1AOC3SLC6A2MAOA
SCHEMBL4433686 1.00 TAAR1 (0.60) TAAR1TRPA1AOC3SLC6A2MAOA
SCHEMBL3672929 0.85 TRPA1 (0.67) TAAR1TRPA1AOC3SLC6A3RIPK1
Hydrochloric Acid SCHEMBL10535795 0.84 TAAR1 (0.58) TAAR1TRPA1AOC3RIPK1ADRA2A
SCHEMBL18266052 0.84 TAAR1 (0.58) TAAR1TRPA1AOC3RIPK1
SCHEMBL7678158 0.83 TAAR1 (0.50) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL9233371 0.82 TAAR1 (0.56) TAAR1TRPA1AOC3RIPK1ADRA2A
SCHEMBL7691241 0.82 TRPA1 (0.59) TAAR1TRPA1AOC3RIPK1ADRA2A
SCHEMBL13335229 0.81 TRPA1 (0.63) TAAR1TRPA1AOC3RIPK1ADRA2A
SCHEMBL11415966 0.81 TAAR1 (0.48) TAAR1SLC6A2MAOASLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106890-A1 SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST OLEMA PHARMACEUTICALS, INC. (US) 2025-05-22 WO disclosed
EP-4366734-A1 METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES Olema Pharmaceuticals, Inc. (US) 2024-05-15 EP disclosed
WO-2023283329-A1 METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES OLEMA PHARMACEUTICALS, INC. (US) 2023-01-12 WO disclosed
EP-3993785-A1 REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS Olema Pharmaceuticals, Inc. (US) 2022-05-11 EP disclosed
WO-2014192973-A1 COMPOUND AND COLORED CURABLE RESIN COMPOSITION 住友化学株式会社 (JP) 2014-12-04 WO disclosed
US-7078406-B2 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) 2006-07-18 US disclosed
US-20040248851-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes Life Technologies Corporation 2004-12-09 US disclosed
US-6815445-B2 FOR USE AS FLUORESCENCE DYES AND PROBES Life Technologies Corporation 2004-11-09 US disclosed
EP-1442027-A1 SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2004-08-04 EP disclosed
US-20030105111-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-06-05 US disclosed
WO-2003031419-A1 SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-04-17 WO disclosed
US-4136100-A BLUE-VIOLET TO GREEN-BLUE DYEINGS ON CELLULOSE TEXTILES BASF AKTIENGESELLSCHAFT (DE) 1979-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248851-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes DHFR, FPR1, CYP1A1 TAAR1 2085/4885TRPA1 2180/4885AOC3 1716/4885
US-20030105111-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes DHFR, FPR1, CYP1A1 TAAR1 2085/4885TRPA1 2180/4885AOC3 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.